STAT+: As controversial decisions mount, FDA shuns public advisory meetings

The FDA is reducing the number of public advisory committee meetings, which has raised concerns among stakeholders, including drugmakers, patients, and doctors. These stakeholders are advocating for greater transparency in the agency's decision-making processes. The reduction in meetings comes at a time when there is a growing demand for opportunities to express views on drug approvals and regulatory practices. This shift has been highlighted by recent controversial decisions, such as the FDA's rejection of an experimental therapy for a rare blood cancer, despite internal reviewers recommending it for approval. This unexpected decision has caused confusion and frustration among advocates for rare diseases, who believed they had received the agency's support for the therapy's clearance (Stat News: STAT+: As controversial decisions mount, FDA shuns public advisory meetings; Stat News: STAT+: A rare disease drug was approvable, then it wasn’t). Additionally, the FDA has issued warning letters to telehealth firms regarding compounded GLP-1 medications, reflecting increased regulatory scrutiny in this area. The agency's actions emphasize the importance of compliance with established safety and efficacy standards within telehealth practices (Stat News: STAT+: FDA warns more telehealth firms about compounded GLP-1s). This regulatory environment is indicative of the challenges that companies must navigate in the biotechnology sector, particularly concerning the safety and efficacy of compounded medications. The ongoing legal complexities in the biotechnology field are also evident in Moderna's recent settlement with Roivant, where Moderna agreed to pay up to $2.25 billion to address claims that its mRNA Covid-19 vaccine infringed on Roivant's patents. This settlement underscores the intricate relationship between intellectual property and the development of Covid-19 vaccines (Stat News: STAT+: FDA warns more telehealth firms about compounded GLP-1s). Overall, the FDA's reduction in public advisory meetings and its regulatory actions highlight the dynamic and often contentious landscape within the biotechnology industry.